We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,259 hedge funds and large institutions have $80B invested in Bristol-Myers Squibb in 2024 Q3 according to their latest regulatory filings, with 266 funds opening new positions, 820 increasing their positions, 929 reducing their positions, and 130 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more first-time investments, than exits

New positions opened: 266 | Existing positions closed: 130

50% more funds holding in top 10

Funds holding in top 10: 1827 (+9)

25% more capital invested

Capital invested by funds: $63.8B → $80B (+$16.2B)

5% more funds holding

Funds holding: 2,1482,259 (+111)

0.63% more ownership

Funds ownership: 75.77%76.4% (+0.63%)

5% less call options, than puts

Call options by funds: $1.88B | Put options by funds: $1.99B

12% less repeat investments, than reductions

Existing positions increased: 820 | Existing positions reduced: 929

Holders
2,259
Holders Change
+111
Holders Change %
+5.17%
% of All Funds
32.43%
Holding in Top 10
27
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+50%
% of All Funds
0.39%
New
266
Increased
820
Reduced
929
Closed
130
Calls
$1.88B
Puts
$1.99B
Net Calls
-$109M
Net Calls Change
+$35.1M
Name Holding Trade Value Shares
Change
Change in
Stake
SC
676
Sapient Capital
Indiana
$2.65M -$13.9K -297 -0.6%
LCOV
677
London Company of Virginia
Virginia
$2.65M -$1.03M -21,886 -30%
GAM
678
Groupama Asset Management
France
$2.64M -$2.46M -52,430 -45%
LGF
679
LGT Group Foundation
Liechtenstein
$2.62M -$295K -6,279 -11%
ATPW
680
Ashton Thomas Private Wealth
Arizona
$2.61M +$862K +18,383 +57%
3IP
681
3Chopt Investment Partners
Virginia
$2.6M +$232K +4,940 +11%
IHL
682
Investment House LLC
California
$2.59M +$219K +4,665 +10%
SAM
683
Sectoral Asset Management
Quebec, Canada
$2.59M +$938K +20,000 +67%
RCA
684
Resonant Capital Advisors
Wisconsin
$2.58M -$64.7K -1,380 -3%
SAM
685
Sompo Asset Management
Japan
$2.58M +$710K +15,140 +44%
STA
686
Summit Trail Advisors
New York
$2.56M +$41.9K +894 +2%
GIA
687
Guyasuta Investment Advisors
Pennsylvania
$2.56M +$47 +1 +0%
CP
688
Castleview Partners
Texas
$2.56M +$2.05M +43,730 +766%
EWA
689
EP Wealth Advisors
California
$2.55M +$461K +9,836 +25%
P
690
Pitcairn
Pennsylvania
$2.53M -$48.4K -1,031 -2%
CAAS
691
Capital Asset Advisory Services
Michigan
$2.53M +$8.91K +190 +0.4%
SHFA
692
SS&H Financial Advisors
Michigan
$2.53M +$82.1K +1,750 +4%
MCM
693
Mill Capital Management
North Carolina
$2.52M -$65.9K -1,405 -3%
SF
694
Slagle Financial
Illinois
$2.51M +$185K +3,935 +9%
PWM
695
Perigon Wealth Management
California
$2.51M +$383K +8,169 +20%
FHB
696
First Hawaiian Bank
Hawaii
$2.51M +$44.6K +951 +2%
HI
697
Horizon Investments
North Carolina
$2.48M +$724K +15,432 +47%
OIA
698
OneDigital Investment Advisors
Kansas
$2.48M -$81.2K -1,731 -3%
BCM
699
Birmingham Capital Management
Alabama
$2.48M +$131K +2,800 +6%
LS
700
Leelyn Smith
Illinois
$2.46M +$187K +3,977 +9%

BMY Hedge Fund Activity: Q3 2024 in Review

2,259 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2024, worth a combined $80B — up 25% from $63.8B a quarter earlier.

Buyers outnumbered sellers: 266 funds opened new BMY positions and 130 closed out — a net gain of 136 holders — while 820 added to existing stakes and 929 trimmed.

The largest buyer was Bank of New York Mellon, adding an estimated $331M. The largest seller was Capital International Investors, cutting an estimated $599M.

  • 2,259 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2024, up from 2,148 in Q2 2024.
  • Funds reported $80B of Bristol-Myers Squibb stock for Q3 2024, up 25% quarter-over-quarter.
  • 266 funds opened new Bristol-Myers Squibb positions in Q3 2024 and 130 closed out, a net change of +136 holders.
  • The largest Bristol-Myers Squibb buyer in Q3 2024 was Bank of New York Mellon, an estimated $331M added.
  • The largest Bristol-Myers Squibb seller in Q3 2024 was Capital International Investors, an estimated $599M sold.

Based on aggregated 13F filings for Q3 2024.